Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease

Livia Brusa, Antonio Orlacchio, Alessandro Stefani, Salvatore Galati, Mariangela Pierantozzi, Cesare Iani, Nicola Biagio Mercuri

Research output: Contribution to journalArticlepeer-review


Since levodopa-induced peak dyskinesias (LIDs) may reflect, in part, a disproportionate phasic release of dopamine from synaptic vesicles, we examined the ability of the vesicular depletor tetrabenazine (TBZ) to reduce LIDs in 10 dyskinetic advanced Parkinson's disease (PD) patients. After basal evaluation, the patients received, through a slow titration, oral TBZ twice a day for six weeks (up to 50 mg daily) before being re-assessed after a challenge with levodopa. The primary outcome measure was the change in the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia score (items 32 to 34). TBZ was well tolerated. A clear treatment effect on LIDs emerged (up to 45%, p

Original languageEnglish
Pages (from-to)101-105
Number of pages5
JournalFunctional Neurology
Issue number2
Publication statusPublished - 2013


  • Parkinson's disease
  • Peak dyskinesia
  • Quality of life
  • Vesicular dopamine
  • Vmat2

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this